Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

What Artelo announced

Artelo Biosciences filed a provisional patent application that claims ART27.13 for the treatment of obesity both as monotherapy and in combination with GLP-1 receptor agonists, citing unexpected nonclinical findings from its DIO-2 study. The company described the filing as intended to secure an early filing date while it pursues further work.

Sources: S1

Key nonclinical DIO-2 findings reported by the company

In obese mice on a high-fat diet, Artelo reported that ART27.13 produced approximately 20% weight loss over four weeks as a monotherapy and approximately 40% weight loss when combined with semaglutide. The company reported that about 80% of the weight lost in ART27.13-treated groups was fat, compared with ~70% with semaglutide alone. Additional reported effects for the combination included greater appetite suppression versus semaglutide alone, improved oral glucose tolerance, increased bone mineral density, and larger reductions in total cholesterol, LDL and HDL when both agents were used together. Artelo said liver hypertrophy was reduced across all treatment groups and that ART27.13 had no observed effect in lean animals on standard chow.

Sources: S1

Product and program context

Artelo described ART27.13 as a peripherally restricted dual cannabinoid CB1 and CB2 receptor agonist with an existing clinical dataset including six completed clinical studies, two ongoing trials, and nearly 300 participants exposed to the compound. The company is running a Phase 2 supportive-care trial in cancer-related anorexia and a Phase 2 study in glaucoma.

Sources: S1

Why it may matter (inference)

If the nonclinical effects translate to humans, ART27.13 could be positioned both as a monotherapy and as a complement to GLP-1 receptor agonists, potentially addressing weight loss magnitude, body composition and bone/lean-mass concerns. The provisional filing expands Artelo’s claimed intellectual property scope into obesity and combination use with GLP-1s.

Sources: S1

What remains uncertain

• All efficacy and metabolic findings cited are from a company-reported nonclinical mouse study (DIO-2); nonclinical results may not predict human outcomes.
• The provisional patent application does not itself grant enforceable rights; it must be followed by a non-provisional filing within 12 months to preserve priority.
• Reported data are preliminary and described in a press release; the full study analysis, independent replication, and peer review were not provided in the source.